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Background: Preoperative imaging is often inadequate in excluding unresectable pancreatic cancer.
Accordingly, many groups employ staging laparoscopy (SL), although none have evaluated SL after
preoperative magnetic resonance imaging (MRI). We performed a retrospective, indirect cost-
effectiveness analysis of SL after MRI for pancreatic head lesions.
Methods: All MRI scans administered for proximal pancreatic cancer between 2004 and 2008 were
reviewed and the clinical course of each patient determined. We queried our billing database to render
average total costs for all inpatients with proximal pancreatic cancer who underwent pancreati-
coduodenectomy, palliative bypass or an endoscopic stenting procedure. We then performed an indirect
evaluation of the cost of routine SL.
Results: The average costs of hospitalization for patients undergoing pancreaticoduodenectomy, open
palliative bypass and endoscopic palliation were: US$26 122.43, US$21 957.18 and US$11 304.00,
respectively. The calculated cost of SL without laparotomy was US$2966.25 or US$1538.61 prior to
laparotomy. The calculated cost of treating unresectable disease by outpatient laparoscopy followed by
endoscopy was US$5943.17. Routine SL would increase our costs by US$76 967.46 (3.6%).
Conclusions: Staging laparoscopy becomes cost-effective by diverting unresectable patients from
operative to endoscopic palliation. Given the paucity of missed metastases on MRI, the yield of SL is
marginal and its cost-effectiveness is poor. Future studies should address the utility of SL by both
examining this issue prospectively and investigating the cost-effectiveness of endoscopic vs. surgical
palliation in a manner that takes account of survival and quality of life data.
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Introduction
Pancreatic cancer presents late in its natural history and thus those
with resectable disease account for only 15–20% of all pancreatic
cancer patients.1–3 Some patients, however, present in time to
undergo pancreaticoduodenectomy – the Whipple procedure –
which offers the only potential cure for malignant lesions in or
around the head of the pancreas. To determine resectability, sur-
geons often choose computed tomography (CT).4,5 Unfortunately,
CT is often inadequate in determining unresectability. Although
the accuracy of CT has improved over time, as many as 10–48% of
those deemed resectable on CT are taken to laparotomy for ulti-
mately unresectable disease.2,5–10 Some studies have explored the
role of magnetic resonance imaging (MRI) in this setting, but
these are few and increasingly dated.4,11–14 Our group recently
reported that, in our experience, MRI offers sensitivity of 100%
for resectable disease and specificity of 73.2–78.9%.15 Although a
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number of patients were taken for laparotomy with what turned
out to be unresectable disease, crucially only six (6.4%) had
metastases, four (4.3%) of which were in the liver. An option
advocated by many groups is to employ staging laparoscopy (SL).
As our group does not regularly use SL in the management of
pancreatic cancer, we performed a cost analysis of this procedure
in the setting of our MRI-driven practice.
The strength of the case for SL is dependent on the yield of
laparoscopy, which is inversely proportional to the quality of pre-
operative imaging and further constrained by the field of laparo-
scopic visualization. Many groups report high yields for SL, which
finds metastases missed on CT in as many as 37% of cases.2,16,17
The prevalence of CT-occult metastases has prompted several
groups to support SL in a manner that presupposes its ability to
detect tumours that are unseen on imaging.18–20 This may give SL
too much credit for four reasons. Firstly, even presuming a lack of
human error, the camera may not capture deep hepatic and low
omental metastases. Indeed, 7–35% of patients receiving SL have
metastases that are later discovered at laparotomy.6,9,17,21,22 Sec-
ondly, the potential yield of SL declines as the accuracy of preop-
erative imaging improves.23 Thirdly, metastases are not the only
reason to abort the Whipple procedure; SL is fundamentally
limited in describing the extent of locoregional disease and its
resectability in terms of vascular invasion. Finally, the unspoken
premise of SL is that the patient with disease that is not amenable
to pancreaticoduodenectomy should be spared a laparotomy. This
is a value judgement based on physician and patient preference for
operative vs. endoscopic palliation that is related, in part, to the
surgical candidacy of the patient.
Justly, several groups have investigated the cost-effectiveness of
SL. Despite their varied conclusions, on balance the data seem to
indicate a small but positive cost : benefit ratio for SL after preop-
erative CT.9,10,21,24–26 Herein, we present a study of the cost-
effectiveness of SL in an MRI-driven practice.
Materials and methods
Assessing the MRI-driven practice
As described in a previous paper,15 we undertook a retrospective
review of all MRI scans administered for suspected pancreatic
cancer at Emory University Hospital in the 4-year period
between December 2004 and December 2008. Institutional
review board approval was ascertained and a Microsoft Excel
database was created to house data for all patients who were
evaluated and treated for this prospective radiographic diagno-
sis. Patient, tumour and radiographic features were reviewed.
Patient factors included age, sex and days between MRI and
operation. Tumour factors included histopathological diagnosis
and nodal status. Radiographic features included comments on
the presence of metastases and the relationship of the tumour
with the surrounding vasculature. In concert with the surgeons,
our radiologists are able to give one of three diagnoses of unre-
sectable, resectable or borderline disease. ‘Unresectable’ disease is
defined as the presence of metastases or significant vascular
invasion or encasement that is clearly not amenable to recon-
structive surgery. In such cases, the diagnosis of pancreatic
cancer is made by open biopsy during a palliative procedure, by
CT-guided biopsy or by endoscopic brushings. These patients
then undergo a palliative procedure, usually of endoscopic
biliary with or without duodenal stenting. ‘Resectable’ disease
denotes the absence of metastases and vascular involvement, and
‘borderline’ disease denotes tumours that significantly abut or
compress otherwise patent vasculature (superior mesenteric
vein, portal vein, hepatic artery, superior mesenteric artery). All
radiological and pathological examinations were carried out at
our institution. Histopathological diagnosis represents the refer-
ence standard.
Cost analysis
Using the experiences derived from the methods described above,
we investigated the cost-effectiveness of incorporating SL for
those patients deemed by radiography to have resectable or bor-
derline resectable disease. Total costs were acquired from our
financial department; these were accurate at April 2009. Total costs
were abstracted directly from accounting ledgers and included the
fixed costs of operations and variable direct costs (labour, supply,
overheads), as well as standard indirect costs. We did not include
any dollar values for which the sum was negotiable, such as pro-
fessional fees. Accordingly, these costs are not charges; they repre-
sent the total cost incurred by the hospital for a given operation.
Average total costs for all patients treated for adenocarcinoma
of the head of the pancreas in a 1-year period (April 2008 to April
2009) were assessed. This group of patients was further divided
according to ICD-9 codes into those who received Whipple pro-
cedures (code 52.7), operative palliative bypasses (codes 51.37 and
44.39) and endoscopic palliative bypasses (codes 51.87 and 52.93),
respectively. These values were derived from data on the hospital-
izations of all patients who received care for pancreatic cancer
delivered by all pancreatic surgeons at our centre. This includes
patients in whom CT alone represented the only preoperative
imaging. The costs of preoperative imaging were not included in
the analysis as these would cancel out across the comparisons.
The costs of inpatient palliative endoscopy were those of the
average patient hospitalized with a diagnosis of pancreatic adeno-
carcinoma and discovered to have metastatic disease on preopera-
tive imaging. Many patients undergo endoscopy as outpatients;
when these patients were considered in our study, we included
only those costs generated in the endoscopy laboratory.
The costs of SL were identified using ICD-9 codes 54.2–54.29.
They were further simplified as the itemized average costs of the
materials, space and ancillary staff manpower. We assumed that
the procedure required 30 min of operating room (OR) time and
30 min of anaesthetist time. We also assumed that the procedure
would be converted to a laparotomy if the SL found no metastases.
Accordingly, the costs of those materials routinely used in laparo-
tomy and therefore already accounted for in the OR costs of the
Whipple or palliative bypass groups were discounted (e.g. bispec-
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tral index [BIS] monitoring, drapes, spontaneous compression
devices, suction, Foley catheter, dermabond, post-anaesthesia
care). If the SL was positive, the average costs of surgical pathology
for patients receiving SL were included. The costs of perioperative
laboratory testing and pharmacology were included explicitly in
our consideration of outpatient laparoscopy, but were already
included in the total cost of these services for hospitalized
patients. This model presumes routine utilization (all patients);
furthermore, it presumes no false negatives (no missed metastases
on laparoscopy) and no intraoperative complications of laparos-
copy (no bleeding or open conversions for unresectable disease).
The cost-effectiveness of laparoscopy was determined in the
following fashion. First, the cost of the MRI-driven practice was
assessed. Second, the cost of treating resectable disease by the
Whipple procedure with laparoscopy was subtracted from that
total to yield the cost of treating unresectable disease. Third, as the
laparoscopy intervention both added cost and reduced the
number of patients receiving operative bypasses by diverting them
towards endoscopic palliation, a formula was constructed to
determine the number of metastases required for laparoscopy to
be cost-effective:
(cost of care for patients with unresectable disease in the MRI-
driven practice) = (total number of patients with unresectable
disease caused by metastases and vascular invasion – x)(cost of
hospitalization with operative bypass and laparoscopy for unre-
sectable disease) + x(cost of hospitalization with endoscopic pal-
liation and laparoscopy for unresectable disease),
where x is the number of metastases found at laparoscopy. This
calculation was repeated with the cost of outpatient management
in place of that of inpatient endoscopic palliation.
Results
The outcomes of an MRI-driven practice
We identified 124 patients who received MRI for preoperative
imaging of suspected pancreatic adenocarcinoma during the
4-year period under review. Thirty patients had unresectable
disease and 94 patients were offered the Whipple procedure. Of
the latter 94 patients, 41 had borderline resectable disease. Eight of
the 94 patients declined an operation and 86 proceeded to the OR,
where 65 received completed Whipple procedures, 20 received
bypass operations and one received an exploratory laparotomy for
benign disease (biopsy-proven pancreatitis). Whipple procedures
were aborted in 11 of the 50 patients (22%) with resectable disease
and 10 of the 36 (28%) patients with borderline resectable disease
who proceeded to the OR (no significant difference). Of the 21
patients in whom Whipple procedures were aborted, 13 were
found to have vascular invasion that was not amenable to recon-
structive surgery, six had metastases that had been missed in pre-
operative imaging and two had benign pathology (chronic
pancreatitis). Of the six patients with occult metastases, four
patients demonstrated metastases in the liver (three on the liver
surface, one in the posterior gallbladder wall) and two showed
metastases in the omentum. The total patient group (n = 124)
included 30 patients with radiographically unresectable disease
secondary to MRI-detected metastases or vascular invasion that
was not amenable to reconstructive surgery. Many of these
patients underwent a procedure to palliate their symptoms which
comprised the placement of plastic biliary stents with or without
duodenal stents and was carried out in the gastroenterology labo-
ratory by an experienced endoscopist.
Determining the costs of operative and
non-operative management
Using ICD-9 codes, we found financial records for all patients
hospitalized for the management of pancreatic adenocarcinoma
between April 2008 and April 2009. These included all of our
institution’s hepatobiliary surgeons’ patients, many of whom did
not receive preoperative MRI. A review of these records yielded
average costs for patients undergoing pancreaticoduodenectomy,
operative bypass and endoscopic palliation; these are summarized
in Table 1.
The average costs of endoscopic palliation were further divided
into those for patients who received the procedure as outpatients
and those for inpatients. We could not determine the proportion
of patients receiving outpatient palliation. Therefore, in determin-
ing the cost of our practice, we included the cost of inpatient
palliation only. In the time under study, 22.3% of patients received
duodenal stenting and 33.3% required anaesthesia. The average
costs incurred by patients receiving endoscopic palliation were
US$2517.50/patient in the endoscopy suite and US$11 304.00/
patient for an entire inpatient hospitalization. As the amount and
type of preoperative imaging were variable, we subtracted the
imaging costs. Incidentally, the cost of an MRI pancreas protocol
was US$498.66, whereas that of a CT pancreas protocol was
US$207.39.
The total cost of hospitalization for the average patient receiv-
ing a Whipple procedure was US$26 122.43. The total cost of an
operative bypass was US$21 957.18 and the total cost of palliative
stenting was US$11 304.00. Therefore, the cost of treating all
patients in this MRI-driven practice series was US$2 159 058.73.
The costs of SL in an MRI-driven practice
The costs of SL are detailed in Table 2. Periprocedure laboratory
and pharmacology costs, which are included in the total costs for
hospitalized patients, are explicitly added to the costs of outpa-
tient laparoscopy in Table 1. From these data we could then derive
the cost of SL with (US$1538.61) or without (US$2966.25) lap-
arotomy (Table 1).
We may then apply these costs to our case series. The cost of
treating our patients with resectable disease by Whipple procedure
is now US$27 661.04; the cost of treating unresectable disease by
palliative double-bypass is now US$23 495.79, and the cost of
treating metastatic disease with SL followed by palliative endos-
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copy in the inpatient setting is US$14 270.29. The total cost of this
practice is therefore US$2 236 026.19.
The costs of outpatient endoscopic palliation are further delin-
eated in Table 2. By combining the costs of endoscopy with those
of laparoscopy and its periprocedure, we can ascertain the costs of
completely outpatient management. The total per patient cost of
this strategy is US$5943.17.
Cost-effectiveness of SL
Staging laparoscopy changes the treatment strategy by redirecting
patients with metastatic disease from the OR to the endoscopy
suite. As endoscopic palliation is cheaper than operative manage-
ment, the more patients who are switched to endoscopy, the
cheaper the practice. However, as there is added cost to utilizing
SL, its cost-effectiveness depends on its yield of metastases. In our
series, 21 patients had unresectable disease at laparotomy and six
of these had metastases. The cost of adding SL directly to the
MRI-driven practice would increase the cost of inpatient manage-
ment by US$76 967.46 (3.6%). If we add the cost of laparoscopy to
that of all procedures, using the formula established earlier, the
number of metastases found on laparoscopy that would render
the procedure cost-effective is 14.30 in inpatient management and
7.54 in outpatient management.
Discussion
The goal of SL is to spare patients with inoperable disease from
laparotomy. Similarly, the cost-effectiveness of SL depends on the
proportion of patients redirected from the OR to the endoscopy
suite and hopefully spared from hospitalization. This proportion
Table 1 Per patient costs of hospitalization for patients treated for pancreatic adenocarcinoma by a Whipple procedure, operative bypass
or endoscopic palliation with stents. The cost of laparoscopy is added to each category. The cost of outpatient management of unresectable
disease is constructed from an itemized list of costs, presuming no hospitalization after laparoscopy
Categories of cost Whipple procedure, US$ Operative bypass, US$ Endoscopic palliation
with stents, US$
Outpatient endoscopic
palliation, US$
Hospital floor 11 631.63 6646.54 4679.76 N/A
OR or GI laboratory 4928.54 5309.02 2517.50 2517.50
Anaesthesia 1148.20 1551.00 219.12 219.12
Surgical pathology 614.27 385.80 See laparoscopy See laparoscopy
Post-anaesthesia care unit 618.25 599.63 See laparoscopy See laparoscopy
Blood bank 812.37 756.35 687.79 N/A
Chemistry laboratory 963.78 700.78 644.46 111.01
Microbiology laboratory 206.69 217.70 138.33 N/A
Pharmacology 3362.72 4153.53 2136.07 129.29
Respiratory 1212.08 991.02 N/A N/A
Rehabilitation 623.90 645.81 280.97 N/A
Total 26 122.43 21 957.18 11 304.00 3415.14
Add laparoscopy 1538.61 1538.61 2966.25 2966.25
New total 27 661.04 23 495.79 14 270.29 5943.17
OR, operating room; GI, gastrointestinal; N/A, not applicable
Table 2 Costs of staging laparoscopy (SL) constructed from an item-
ized list of costs derived from financial records at our institution
Categories of cost Costs of
SL alone, US$
Add to costs
of laparotomy?
Post-anaesthesia care 400.38 No
Trocars 415.04 Yes
Scissor tip 46.30 Yes
Warmer seals 4.50 Yes
Insufflation tubing 7.78 Yes
Bovie pieces 10.91 No
Harmonic scalpel 486.59 Yes
Bair hugger 13.77 No
Urine meter 22.49 No
Sterile drape set 44.88 No
Suction set 45.57 No
Staplers 14.24 No
Spontaneous compression
device
24.65 No
Bispectral index monitor 24.01 No
Intravenous tubing and kit 40.68 No
Chlorhexidine 6.06 No
Dermabond 2 pack 62.90 No
Operating room time (30 min) 396.00 Yes
Anaesthetist (30 min) 182.40 Yes
Surgical pathology 717.10 No
Total 2966.25 1538.61
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further depends on the number of metastases discoverable at lap-
arotomy and thus the number of metastases missed on preopera-
tive imaging. Beyond these considerations, the value of SL
depends on surgeon and patient preference for operative vs. endo-
scopic palliation. Staging laparoscopy is only useful if endoscopic
palliation is preferred over operative bypass in operative candi-
dates. We found that, for SL to be cost-effective, the number of
metastases detected at SL had to be greater than the number
missed by preoperative MRI, even if metastatic disease was
managed entirely on an outpatient basis. Given the paucity of
MRI-occult metastases, in this cost-effectiveness analysis of SL in
an MRI-driven practice, we find that SL is not a cost-effective
procedure.
These results are strengthened by the advantages conferred
upon SL by the study’s five simplifying assumptions. It was
assumed, first, that SL would detect all MRI-occult metastases;
second, that SL would have no complications; third, that SL would
not lengthen the hospitalization; fourthly, that SL could be under-
taken entirely on an outpatient basis. Finally, we made our calcu-
lations on the assumption that all patients receiving palliative
endoscopy in the non-SL group were inpatients, but that patients
in the SL group received palliation as outpatients, adding consid-
erable cost to the MRI-driven practice.
These assumptions were very kind to SL. Prior studies of SL
show a 1.7–5.1% rate of minor complications, a 0.7–2.3% rate of
major complications (requiring conversion to an open procedure
or transfusion) and a 0.49% rate of death.27,28 Although our
methods capture the added hospital costs associated with open
procedures (i.e. they represent the average total costs of hospital-
ization for all patients undergoing operative management), they
do not capture those incidental costs that may be associated with
SL. Furthermore, although this may reflect either the location
of the deposit or operator error, 7–35% of patients receiving
SL are found to have metastases that are discovered at
laparotomy.6,9,17,21,22
For these reasons, SL has become controversial. Some practitio-
ners endorse the practice for all patients with radiographically
resectable disease9,24 and some concede that its role is marginalized
by good preoperative imaging.21,23 Others propose that SL should
be applied selectively in those patients with specific clinical fea-
tures that have been shown retrospectively to predict the presence
of occult metastases, such as extreme back pain, weight loss,
elevated tumour markers and tumours located in the pancreatic
tail.5,10,25,29 None of these studies, however, have evaluated the
utility of SL after a preoperative MRI and no study has addressed
whether it is best to redirect patients who are candidates for intra-
abdominal surgery from operative to endoscopic bypasses.
Our study has limitations. Firstly, this is a retrospective study
and therefore subject to the limitations intrinsic to this sort of
inquiry. Secondly, we did not study the clinical presentations of
our patients and therefore we cannot comment on the use of a
selective approach to SL. Thirdly, these costs are those of our
institution alone and therefore limit the generalizability of our
findings. Fourthly, our study represents an indirect evaluation of
SL: the added cost of SL is a calculation based on the costs delin-
eated in Table 2. However, the costs presented are generously low.
Furthermore, by granting several advantages to SL in this indirect
evaluation, including perfect yield, we have presented the upper
limit of this practice’s cost-effectiveness.
This study of our institution’s experience with preoperative
MRI in the treatment of pancreatic head lesions does not support
the incorporation of routine SL. Further studies are needed to
prospectively determine the cost-effectiveness of this procedure in
both CT- and MRI-driven practices. Additionally, the value of SL
ought to be determined by investigating the optimal approach to
patients with inoperable disease using cost-effectiveness data that
take account of data on mortality and quality of life after each
procedure.
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